HNRNPU and non-small cell lung carcinoma: In the analysis of the TCGA data, NSCLC patients with high mRNA HNRNPU tended to survive for shorter periods than those with low expression (median OS of 1528 vs. 2086 days; HR = 1.26, 95% CI 0.99–1.60; p = 0.061; Table 4; Fig. 3d).